|Articles|March 1, 2013
- Pharmaceutical Executive-03-01-2013
- Volume 0
- Issue 0
PE, March 2013 Cover Image
S
Advertisement
Cover
Articles in this issue
about 13 years ago
Less Selling, More Timeabout 13 years ago
Test and Learn: Making Confident Decisions on the Commercial Sideabout 13 years ago
Specialty Service Programs: Gearing up for Next Generation Technologiesabout 13 years ago
China and the Emerging Markets Challengeabout 13 years ago
Embedding Market Access in Today's Pharma Business Modelabout 13 years ago
Who's Really in Charge of European Drug Registration?about 13 years ago
Brand of the Year: Januviaabout 13 years ago
Early Engagement with Medical Laboratoriesabout 13 years ago
Pharma in the News: Pharm Exec's Annual Press Auditabout 13 years ago
Safeguarding the Value of Patent AssetsAdvertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Datroway for Patients with Metastatic Triple-Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates
2
What Kinds of Disruption are GLP-1s Expected to Face
3
Eli Lilly and Novo Nordisk Shift Patients From Compounded Drugs to Lower-Cost Weight-Loss Pills: Report
4
The Evolving Relationship Between FDA and Biotech
5